際際滷

際際滷Share a Scribd company logo

FDA Approves New Breast Cancer Treatment Drug

Download as PPTX, PDF
Eloah Rocha
Eloah Rocha

The FDA approved Roche's Tecentriq as the first immunotherapy drug for treating advanced triple-negative breast cancer. A study found patients taking Tecentriq with chemotherapy went two months longer without worsening conditions. While expensive and with modest results, Tecentriq improves the immune system's ability to detect and kill cancer cells, representing an important breakthrough for this type of breast cancer.

1 of 5
Download to read offline
FDA Approves New Breast Cancer Treatment Drug By: Eloah Rocha
FDA Approves New Breast Cancer Treatment Drug The recipient of a bachelor's degree in child psychology from the University of Colorado Boulder, Eloah Rocha has served as a youth counselor at Children's Hospital Los Angeles since 2004. In addition to her work, Eloah Rocha is a supporter of causes that benefit breast cancer patients.
FDA Approves New Breast Cancer Treatment Drug A potentially impactful breakthrough was made in regard to breast cancer on March 11, 2019, as the US Food and Drug Administration (FDA) approved Roche's Tecentriq for the treatment of advanced triple-negative breast cancer, which accounts for roughly 15 percent of all breast cancer cases. Tecentriq, which is to be used in combination with chemotherapy, is the first FDA-approved immunotherapy drug used to treat breast cancer.
FDA Approves New Breast Cancer Treatment Drug The approval comes after a study of 900 women found that subjects who took Tecentriq and underwent chemotherapy continued an average of two months longer without experiencing worsening conditions. Tecentriq, which costs $13,400 per month, improves the immune system's ability to detect and kill cancerous cells.
FDA Approves New Breast Cancer Treatment Drug While Tecentriq is an expensive drug with only modest results in stalling the progression of breast cancer, it's a first-of-its-kind breakthrough that represents a significant step forward in understanding and treating advanced triple-negative breast cancer.

More Related Content

FDA Approves New Breast Cancer Treatment Drug

  • 1. FDA Approves New Breast Cancer Treatment Drug By: Eloah Rocha
  • 2. FDA Approves New Breast Cancer Treatment Drug The recipient of a bachelor's degree in child psychology from the University of Colorado Boulder, Eloah Rocha has served as a youth counselor at Children's Hospital Los Angeles since 2004. In addition to her work, Eloah Rocha is a supporter of causes that benefit breast cancer patients.
  • 3. FDA Approves New Breast Cancer Treatment Drug A potentially impactful breakthrough was made in regard to breast cancer on March 11, 2019, as the US Food and Drug Administration (FDA) approved Roche's Tecentriq for the treatment of advanced triple-negative breast cancer, which accounts for roughly 15 percent of all breast cancer cases. Tecentriq, which is to be used in combination with chemotherapy, is the first FDA-approved immunotherapy drug used to treat breast cancer.
  • 4. FDA Approves New Breast Cancer Treatment Drug The approval comes after a study of 900 women found that subjects who took Tecentriq and underwent chemotherapy continued an average of two months longer without experiencing worsening conditions. Tecentriq, which costs $13,400 per month, improves the immune system's ability to detect and kill cancerous cells.
  • 5. FDA Approves New Breast Cancer Treatment Drug While Tecentriq is an expensive drug with only modest results in stalling the progression of breast cancer, it's a first-of-its-kind breakthrough that represents a significant step forward in understanding and treating advanced triple-negative breast cancer.